This Month in JNM

Imaging glutamine metabolism: Rajagopalan and DeBerardinis review the essential aspects of glutamine metabolism in cancer cells and discuss both current and future opportunities for imaging in cancer patients.Page 1005

¹⁸F-FDG and the diabetic foot: Palestro looks at reasons for disagreement in available data on the role of PET and PET/CT in the evaluation of diabetic foot infections and previews a related article in this issue of JNM.Page 1009

Sequential PET/CT in the diabetic foot: Familiari and colleagues use sequential ¹⁸F-FDG PET/CT in diabetic patients with high suspicion of osteomyelitis to define objective interpretation criteria and compare results with those from white blood cell scintigraphy.Page 1012

Dual-tracer plaque imaging: Derlin and colleagues compare macrophage activity as determined by ¹⁸F-FDG PET and ongoing mineral deposition as measured by ¹⁸F-sodium fluoride PET in atherosclerotic plaque and correlate these findings with CT-assessed calcified plaque burden.Page 1020

Decreasing pediatric PET/CT dose: Alessio and colleagues determine whether shorter acquisition durations or lower ¹⁸F-FDG injected activity could be used for pediatric ¹⁸F-FDG PET/CT examinations while maintaining diagnostic utility.Page 1028

Fetal radiation exposure from PET: Takalkar and colleagues estimate the fetal radiation exposure resulting from ¹⁸F-FDG PET procedures performed in pregnant women with malignancies.Page 1035

¹⁷⁷Lu-DOTATATE in neuroblastoma: Gains and colleagues report on a study designed to determine whether ⁶⁸Ga-DOTATATE PET/CT can select children with primary refractory or relapsed high-risk neuroblastoma for treatment with ¹⁷⁷Lu-DOTATATE and whether this is a viable therapeutic option.Page 1041

Hypoxia and metastatic renal cancer: Hugonnet and colleagues use ¹⁸F-fluoromisonidazole PET/CT to assess initial tumor hypoxia in metastatic renal cell carcinoma and changes after sunitinib treatment and explore the possible prognostic utility of these data.Page 1048

Complementary PET and MRI data: Choi and colleagues investigate whether apparent diffusion coefficient values from diffusion-weighted MRI and standardized uptake values from ¹⁸F-FDG PET/CT can be effectively correlated in patients with head and neck squamous cell carcinoma.Page 1056

Sodium perchlorate in radioembolization: Sabet and colleagues determine whether oral administration of NaClO₄ before ^99mTc-macroaggregated albumin scanning will improve radioembolization accuracy by blocking free ^99mTc-pertechnetate gastric uptake.Page 1063

SPECT/CT prostate lymphoscintigraphy: Seo and colleagues describe a clinical procedure for mapping lymphatic drainage from the prostate using SPECT/CT and filtered ^99mTc-sulfur nanocolloid as an alternative to a proprietary product not approved in the United States.Page 1068

GLP-1 and sst₂ receptors in insulinomas: Wild and colleagues report on a study designed to assess the roles of glucagon-like peptide-1 imaging and somatostatin receptor subtype 2 imaging in management of patients with malignant insulinomas.Page 1073

MPI versus CTA: Tamarappoo and Hachamovitch provide an education overview of advances in CT coronary angiography and myocardial perfusion imaging and discuss the relative merits of anatomy- and physiology-based testing in patients with known or suspected coronary artery disease.Page 1079

¹²³I-MIP-1072 and tumor mass: Hillier and colleagues explore the utility of this prostate-specific membrane antigen–targeting agent in monitoring paclitaxel therapy in in vitro and xenograft studies.Page 1087

Imaging of COX-1 in neuroinflammation: Shukuri and colleagues describe ex vivo and in vivo studies with an ¹¹C-labeled ketoprofen methyl ester PET probe that targets cyclooxygenase-1 and -2 for imaging neuroinflammation.Page 1094

PET reporter gene system for brain: Vandeputte and colleagues report on animal studies validating a PET reporter system for imaging gene expression in the intact brain, using human type 2 cannabinoid receptors.Page 1102

⁶⁴Cu- or ⁶⁸Ga-somatostatin antagonists: Fani and colleagues describe the development and analysis of four ⁶⁴Cu or ⁶⁸Ga radioantagonists for PET of somatostatin receptor subtype 2–positive tumors.Page 1110

PET and hepatic blood perfusion: Winterdahl and colleagues detail a PET method for quantification of hepatic blood perfusion using blood-to-cell clearance of ¹⁸F-FDG, 3-O-¹¹C-methylglucose, or 2-¹⁸F-fluoro-2-deoxy-D-galactose without the need for portal venous blood samples.Page 1119

Islet cell ¹⁸F-fallypride PET: Garcia and colleagues introduce a novel dopamine D₂/D₃ receptor–based PET method to study islet cells in the rat pancreas and in islet cell transplantation.Page 1125

PET of D₂ receptors in mice: Fischer and colleagues use ¹¹C-raclopride to test the feasibility of the multiple-ligand-concentration receptor assay for D₂ receptor quantification in mice and discuss the potential for assessing receptor expression and gene function.Page 1135

Attenuation correction for PET/MRI: Malone and colleagues compare 2 modeled approaches to produce accurate attenuation correction for brain PET scans on combined PET/MRI systems.Page 1142

Transporter occupancy of SEP-225289: DeLorenzo and colleagues describe an open-label PET study to investigate the dopamine and serotonin occupancy of this novel transporter inhibitor and discuss potential applications in the drug development process.Page 1150

Commentary on dosimetry: Stabin and colleagues from the SNM Radiation Dose Assessment Resource task group provide an overview of the current status of radiation dosimetry in nuclear medicine and its evolution toward patient-specific applications.Page 1156

Cardiovascular nuclear imaging: Members of the SNM Cardiovascular Council Board of Directors summarize appropriate-use criteria and guidelines for minimizing radiation exposure and optimizing the clinical use of radionuclide cardiac imaging studies.Page 1162

ON THE COVER

Shorter ¹⁸F-FDG PET/CT acquisitions can be used for pediatric examinations without loss of diagnostic utility. The reduced scan time decreases the potential for motion artifacts, improves patient comfort, and decreases the length of sedation. In the example shown here, a 61-kg patient was imaged at 1, 2, 3, and 5 min per field of view, and all acquisition durations in this instance were graded as adequate.See page 1031.

• © 2011 by Society of Nuclear Medicine